Compare · INDV vs NVO
INDV vs NVO
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 43.8x INDV ($3.97B).
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 7 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.97B
- $173.66B
- 1M return
- -9.22%
- -
- 1Y return
- +32.45%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INDV
- SEC Form 8-K filed by Indivior Pharmaceuticals Inc.
- SEC Form 425 filed by Indivior Pharmaceuticals Inc.
- SEC Form 8-K filed by Indivior Pharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.
- SEC Form 425 filed by Indivior Pharmaceuticals Inc.
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form EFFECT filed by Indivior Pharmaceuticals Inc.
- SEC Form 424B3 filed by Indivior Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank